Navigation Links
Numira Biosciences Names New Board Member
Date:3/5/2008

Drug discovery and development veteran Paul Grint, M.D. brings extensive

experience to Numira

IRVINE, Calif., March 5 /PRNewswire/ -- Numira Biosciences announced the appointment of Paul Grint, M.D., to its Board of Directors.

Currently, Dr. Grint serves as the Chief Medical Officer and Head of Development at Kalypsys, Inc., a drug discovery and development company based in San Diego, CA. Prior to Kalypsys, he held senior management positions at Zephyr Sciences, Pfizer Global Research & Development, IDEC Pharmaceuticals, and Schering-Plough. Additionally, he is a member of the Board of Directors at Illumina Inc. and serves as Chairman of the Advisory Council of the Keck Graduate Institute.

"We are very pleased to have attracted an industry leader of Dr. Grint's caliber," said Michael Beeuwsaert, President and CEO of Numira. "His extensive background in drug discovery and development will be invaluable to us as we head into our next phase of growth."

About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company's website at http://www.numirabio.com.


'/>"/>
SOURCE Numira Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: